Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Opicinumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SYNERGY
  • Sponsors Biogen

Most Recent Events

  • 12 Oct 2018 Results assessing biomarkers of remyelination and patient stratification for opicinumab treatment effect, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
  • 28 Oct 2017 Results of a post-hoc analysis studying demographic and baseline predictors of opicinumab treatment response, and identifying a subpopulation with a greater treatment response presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
  • 18 Oct 2017 Data from this trial will be presented at the ECTRIMS-ACTRIMS 2017 meeting, according to a Biogen media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top